Dhuwit awis saben saham ProKidney Pharma (PROK)

ProKidney Pharma - logo grafis emiten PROK

ProKidney Corp. (PROK) focuses on implementing cell technologies for the therapy of advanced kidney failure, seeking approval from US regulators. The operating model is based on the full outsourcing of production and testing. This chart of cash reserves per share confirms financial stability, where 0.46 serves as the current parameter value. The patent uniqueness of the organ restoration method guarantees global scalability with minimal costs.

Dhuwit awis saben saham ProKidney Pharma (PROK): kanggo periode 28.04.2023 - 20.11.2026

Rincian metrik komprehensif lan analitis ProKidney Pharma (PROK)

- rega pasar lan target rega analis:
- indikator anane dhuwit lan arus kas:
Analisis umum perusahaan:PROK (ProKidney Corp.)
Sampel barang ProKidney Inc.

Funding kidney cell therapy research in partnership with nephrology centers requires significant expenditures, which directly impacts the liquid asset volume of ProKidney Corp. (PROK). This metric is calculated by dividing total cash by the number of shares to determine the actual equity value and the issuer's financial stability, clearly reflecting the projected cash per share.